Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $32.00.

Several research firms recently issued reports on ODTX. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Wedbush started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price objective on the stock. TD Cowen initiated coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a “buy” rating for the company. Finally, Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th.

Odyssey Therapeutics Stock Performance

Shares of Odyssey Therapeutics stock opened at $18.66 on Wednesday. The firm has a fifty day simple moving average of $17.45. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, June 17th. The company reported ($6.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($5.46).

Insider Activity

In related news, Director Shelley Chu acquired 11,111 shares of the business’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $18.00 per share, with a total value of $199,998.00. Following the completion of the acquisition, the director owned 11,111 shares in the company, valued at $199,998. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Friday, May 8th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $19,999,998.00. Following the purchase, the director directly owned 3,333,516 shares in the company, valued at $60,003,288. This represents a 50.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 4,183,777 shares of company stock valued at $75,319,986.